Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose (dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide

NCT01092559

Pulmonary Arterial Hypertension

COMPLETED PHASE2

Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide

NCT02436512

Pulmonary Arterial Hypertension

WITHDRAWN PHASE3

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

NCT03727451

Pulmonary Hypertension Pulmonary Fibrosis Sarcoidosis, Pulmonary

COMPLETED PHASE2

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT05747508

Pulmonary Fibrosis Pulmonary Hypertension

UNKNOWN PHASE2

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

NCT03267108

Pulmonary Fibrosis Pulmonary Hypertension

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Up to 54 subjects undergoing RHC are planned in this study, and shall include subjects meeting eligibility criteria classified as WHO Group 1 PAH or WHO Group 3 IPF-PH. Subjects will receive inhaled nitric oxide from the GeNOsyl® System to characterize the hemodynamic response and evaluate safety and tolerability.

Dose cohorts of approximately 5, 15, and 20 ppm nitric oxide in air will be studied. Different dose levels will be achieved by varying the flow rate of the drug substance (80 ppm NO2 in balance air) delivered to the subject via nasal cannula. Each subject will receive two different doses of inhaled nitric oxide separated by a placebo (medical grade air or supplemental oxygen) washout. Eligible subjects will be assigned to a dosing cohort in an escalating manner to receive study drug (80 ppm nitric oxide in air.)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension Idiopathic Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dosing Group 1

1 Liter per Minute (LPM)of inhaled nitric oxide via nasal cannula: approximately 5 parts per million (ppm)

Group Type EXPERIMENTAL

Inhaled Nitric Oxide

Intervention Type DRUG

Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM

Dosing Group 2

2 LPM of inhaled nitric oxide via nasal cannula: approximately 15 ppm

Group Type EXPERIMENTAL

Inhaled Nitric Oxide

Intervention Type DRUG

Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM

Dosing Group 3

4 LPM of inhaled nitric oxide via nasal cannula: approximately 20 ppm

Group Type EXPERIMENTAL

Inhaled Nitric Oxide

Intervention Type DRUG

Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inhaled Nitric Oxide

Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM

Intervention Type DRUG

Inhaled Nitric Oxide

Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM

Intervention Type DRUG

Inhaled Nitric Oxide

Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GeNOsyl GeNOsyl GeNOsyl

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

PAH and PH-IPF

* WHO Functional Class (or equivalent classification) II - IV.
* Subjects using supplemental oxygen must be receiving a stable course of therapy for a minimum of 14 days prior to study drug administration.
* All subjects' oxygen saturation must be \> or = to 88% at time of treatment
* Echocardiogram within 6 months of baseline showing no signs of clinically significant left sided heart disease
* Females of child-bearing potential with a negative urine pregnancy test, or a documented surgical sterilization, or is post-menopausal prior to administration of investigational product. Females of childbearing potential must be practicing adequate birth control.

PAH (WHO Group 1) ONLY-Inclusion

* Documented diagnosis of WHO Group 1 PAH, (limited to, idiopathic, heritable, drug and toxin induced, associated with connective tissue disease, portal hypertension, repaired congenital heart disease, HIV); documented by a previous RHC and hemodynamics consistent with PAH, WHO Group 1
* Pulmonary Function Testing within 6 months prior to screening/enrollment shows no evidence of interstitial lung disease (TLC\<70%) or obstructive lung disease (FEV1/FVC ratio \<50%)
* Receiving a stable course of approved PAH oral mono therapies for a minimum of 14 days prior to treatment period
* Must be 18-80 year of age

PH-IPF (WHO Group 3) ONLY-Inclusion

* Documented diagnosis of probable or definite IPF using ATS/ERS criteria
* Previous transbronchial biopsy, if performed, shows no features to support a definitive alternative diagnosis
* Previous bronchoalveolar lavage, if performed, shows no features that provides an alternative diagnosis
* FVC \> or = 40% within 6 months of baseline visit
* Diagnosis of PH based on hemodynamic requirements
* Age 40-85.
* Diagnosis of IPF \> or = 3 months prior to study drug administration
* Diagnosis of PH based on the following hemodynamic criteria (PAPm \> or = 25 mmHg (at rest) / PCWP or LVED \< or =15 mmHg and / PVR \>3 Wood Units)

Exclusion Criteria

PAH and PH-IPF

* Have any other disease associated with pulmonary hypertension (i.e. Group II, IV or V).
* Documented uncontrolled systemic hypertension.
* Left ventricular ejection fraction (LVEF) \< 40%.
* Have chronic kidney disease stage IV or worse, or requires dialysis.
* Be receiving an investigational drug, have in place an investigational device, or have participated in an investigational drug study within past 30 days.
* Have had an atrial septostomy.
* Have anemia or any other ongoing condition that would interfere with the interpretation of study assessments.
* Have any serious or life-threatening disease other than conditions associated with PAH or PH-IPF (e.g. malignancy requiring aggressive chemotherapy, renal dialysis, etc.)
* Significant, ongoing alcohol or drug abuse, or unstable psychiatric status.
* Receiving inhaled or parenteral prostacyclins or a non-approved combination of approved oral PAH therapy.
* Pregnant or lactating subjects

PAH (WHO Group 1) ONLY-Exclusion

* Have had any changes to chronic therapy (including but not limited to oxygen, a different category of vasodilator, a diuretic, digoxin) for PAH added within 14 days of study drug administration. Anticoagulants are allowed to be discontinued per institutional standard of care.
* History of untreated sleep apnea within three months of study drug administration.
* History of hemodynamically significant left-sided heart disease or evidence of left-sided heart disease.

PH-IPF (WHO Group 3) ONLY-Exclusion

* Diagnosis of PH primarily due to etiology other than IPF.
* FEV/FVC ratio \< 60% documented within 6 months of baseline visit.
* Hospitalization for acute exacerbation of IPF within 30 days of baseline visit.
* Recent active pulmonary or upper respiratory tract infection.
* Receiving any approved PAH therapy within 30 days of study drug administration.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No